Relief s.r.l.

Relief s. r. l. focuses on medical innovation, specializing in the development and commercialization of advanced devices for treating stress urinary incontinence, directly impacting patient care in urology.

Founded in 2019 in Italy, Relief s. r. l. is dedicated to creating medical devices for healthcare professionals.

The company raised its latest funding on March 5, 2025, marking its commitment to advancing technology in medical treatments. The founder’s previous entrepreneurial experience is not publicly detailed. Relief S. r.

l. specializes in the development and commercialization of UroRelief, an innovative endo-urethral medical device designed specifically for the treatment of stress urinary incontinence (SUI). This medical device is a sterile, single-use product that is inserted into the urethra via a routine endoscopic procedure, typically performed under local anesthesia in an outpatient setting. UroRelief works by bypassing the urethral sphincter and positioning a silicone valve at the bladder neck, effectively replacing the function of the biological external urinary sphincter.

The device is unisex, discreetly invisible outside the body, and requires no special training for patients, making it suitable for both male and female users. Relief S. r. l.

primarily targets markets in Europe and the United States, focusing on healthcare providers, urologists, and hospitals that treat patients suffering from SUI. Relief S. r. l.

's revenue model is structured around direct sales of its flagship product, UroRelief, to healthcare facilities and practitioners. The company engages in B2B transactions, primarily selling its medical devices to urologists and hospitals that provide treatment for patients with SUI. This approach allows Relief to maintain a strong connection with healthcare providers who directly administer the device to patients. The pricing structure is tailored to healthcare institutions, enabling them to offer UroRelief as part of their treatment options for SUI.

Revenue generation is further supported by partnerships with medical manufacturers and distributors to expand market reach and optimize production capabilities. In March 2025, Relief s. r. l.

raised an undisclosed amount of venture funding led by new investor Panakes Partners, with participation from other new investors Exor Ventures and Club Degli Investitori, as well as returning investor Santex S. p. A. The company will use the funding to advance technology development, complete clinical validation, support regulatory activities, expand its team, and enhance industrial capabilities.

Moving forward, Relief plans to enhance its product lineup with new innovations targeting SUI and aims to expand into new geographic markets, particularly within Europe and North America, by the end of 2026.